Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8701 · 1 trial · 9 indications
Determined according to Incidence and treatment related AEs and SAEs
Determined according to Incidence of DLTs (during the first 28 day cycle)
Determined according to Incidence of abnormal vital signs and laboratory parameters
Safety and tolerability of the MTD/OBD/MFD assessed through incidence of AEs and SAEs
The proportion of subjects achieving a confirmed complete or partial response according to RECIST 1.1 by investigator assessment
| Arm | Type | Description |
|---|---|---|
| Monotherapy | EXPERIMENTAL | Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years. |
| Combination Therapy | EXPERIMENTAL | Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years. |
| Name | Type | Description |
|---|---|---|
| AZD8701 | DRUG | FOXP3 antisense oligonucleotide |
| Durvalumab | BIOLOGICAL | anti PDL-1 monoclonal antibody |
Inclusion Criteria: The study is comprised of 2 main parts Monotherapy (AZD8701) and Combined Therapy (AZD8701 and Durvalumab). Inclusion criteria Dose escalation stages: * Histological or cytological confirmation of a solid, malignant tumour including HNSCC, TNBC, NSCLC, ccRCC, gastroesophageal ...
AZD8701 is an investigational small molecule being studied for the treatment of clear cell renal cell cancer, as well as other advanced solid tumors including non-small-cell lung cancer, triple negative breast cancer, head and neck squamous cell cancer, small cell lung cancer, gastroesophageal cancer, melanoma, and cervical cancer.
AZD8701 is a small molecule developed by AstraZeneca. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated in combination with durvalumab, an anti-PD-L1 antibody, in patients with advanced solid tumors.
AZD8701 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for the treatment of advanced solid tumors.
AZD8701 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study of AZD8701, with or without durvalumab, has been completed in participants with advanced solid tumors.
AZD8701 has been studied in one clinical trial, identified as NCT04504669, titled 'First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours'. This Phase 1 trial enrolled 60 participants and has been completed. The study was conducted in the United States, Canada, France, and Spain.
No, AZD8701 is not the same as durvalumab. AZD8701 is an investigational small molecule being developed by AstraZeneca, while durvalumab is an anti-PD-L1 monoclonal antibody. In the clinical trial NCT04504669, AZD8701 was studied both alone and in combination with durvalumab.